HBW-012462

Part 1: Dose Escalation and PK Expansion Phase (Phase I) (1) Primary Objective ●Evaluate the safety and tolerability of HBW-012462 in patients with locally advanced or metastatic solid tumors harboring KRAS mutations, explore the MTD of HBW-012462, and recommend a reasonable dosing regimen (RP2D) for the Phase II clinical trial. (2) Secondary Objectives ●Evaluate the PK characteristics of HBW-012462 in patients with locally advanced or metastatic solid tumors harboring KRAS mutations; ●Evaluate the preliminary antitumor efficacy of HBW-012462 in patients with locally advanced or metastatic solid tumors harboring KRAS mutations. Part 2: Dose Expansion Phase (Phase II) (1) Primary Objective ●Evaluate the objective response rate (ORR) of HBW-012462 in patients with locally advanced or metastatic solid tumors harboring KRAS mutations. (2) Secondary Objectives ●Evaluate other efficacy endpoints of HBW-012462 in patients with locally advanced or metastatic solid tumors carrying KRAS mutations; ●Evaluate the safety of HBW-012462 in patients with locally advanced or metastatic solid tumors carrying KRAS mutations; ●Evaluate the PK characteristics of HBW-012462 in patients with locally advanced or metastatic solid tumors carrying KRAS mutations.